It’s Time to Transform Dementia Assessment
Nearly half of all dementia cases go undiagnosed.
The SPARK Scan is here to change that.
Dementia Today
The Stats Are Staggering
Americans live with dementia today, and that is projected to double by the year 2050.
Dementia cases go undiagnosed, worsening outcomes and raising costs.
Of PCPs report not having enough time to properly assess for dementia.
The average time people live with dementia before finally receiving a diagnosis.
There’s a solution
Meet the Next Generation Dementia Screener
We are SPARK Neuro, developers of the SPARK Scan, and leader in A.I.-based neurological assessment.
Developed in collaboration with The Mayo Clinic, Johns Hopkins, and MIT, the SPARK Scan combines advanced machine learning with EEG technology to accurately and objectively assess cognitive health in minutes.
That means patients get the care they need, faster. Doctors save time, focusing their efforts where they’re needed most. And payers and plans see improved diagnostic efficiency.
The SPARK Scan is:
- An FDA cleared, Class-II Device
- Simple, accurate, and non-invasive
- Available at-home or in-clinic
- Available as a full-service offering
SCreening Needs To ChANGE
The SPARK Scan Leads The Way
Most dementia screeners have a high false positive rate of 4:5, so physicians evaluate healthy people nearly half of the time.
Thanks to our very low false positive rate of 1:4, the SPARK Scan accurately identifies the right patients to focus on.
That saves time and lowers stress for physicians and patients alike.
Improve Outcomes
Early intervention with better diagnosis can delay up to 40% of dementia cases.
Save Time
Help physicians focus on diagnosis and treatment by reducing false positives.
Lower Costs
Early diagnosis could save up to $7.9T a year via better care and patient management.
Boost Satisfaction
Only 16% of patients receive the proactive cognitive assessment they expect.
The spark scan solution
The Next Generation of Dementia Screening
Accurate Assessment
Our A.I. algorithms unlock the power of EEG for objective neurological analysis.
Safe & Non-Invasive
FDA cleared, Class-II device, built to the highest standards of safety and efficacy.
Simple for Everyone
Accessible to all, and available at home or in-clinic, all in a matter of minutes.
our Advisors
Guided by the Best and Brightest
Dr. Vanessa Raymont
University of Oxford Sr. Clinical Researcher, R&D Director at Oxford Health NHS Foundation Trust
Dr. Howard Fullman
Former Medical Director and Chief of Staff at Kaiser Permanente
Dr. Jonathan Fielding
Former Director of the Los Angeles County Department of Public Health, and Distinguished Professor at UCLA’s Fielding School of Public Health
Dr. Shubhendu Trivedi
Research Associate at MIT’s Computer Science and Artificial Intelligence Laboratory